Impact of Proteinuria on Renal Outcomes in the BALANCE Trial
Status PubMed-not-MEDLINE Jazyk angličtina Země Spojené státy americké Médium electronic-ecollection
Typ dokumentu časopisecké články
PubMed
41531439
PubMed Central
PMC12794064
DOI
10.1016/j.ekir.2025.11.016
PII: S2468-0249(25)00701-6
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Chiesi Canada Corp Woodbridge Ontario Canada
Chiesi Farmaceutici S p A Parma Italy
Chiesi USA Inc Boston Massachusetts USA
Division of Nephrology University of Alabama at Birmingham Birmingham Alabama USA
Zobrazit více v PubMed
Germain D.P., Linhart A. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease. Front Genet. 2024;15 doi: 10.3389/fgene.2024.1395287. PubMed DOI PMC
Wallace E.L., Goker-Alpan O., Wilcox W.R., et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet. 2024;61:520–530. doi: 10.1136/jmg-2023-109445. PubMed DOI PMC
Wallace E.L., Goker-Alpan O., Bernat J.A., et al. 2024. The Impact of Baseline Proteinuria on Renal Outcomes in the BALANCE Study of Pegunigalsidase Alfa vs Agalsidase Beta in Fabry Disease. Poster Presented at the 8th Fabry Disease Update.
Turin T.C., James M., Ravani P., et al. Proteinuria and rate of change in kidney function in a community-based population. J Am Soc Nephrol. 2013;24:1661–1667. doi: 10.1681/ASN.2012111118. PubMed DOI PMC
Schiffmann R., Warnock D.G., Banikazemi M., et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24:2102–2111. doi: 10.1093/ndt/gfp031. PubMed DOI PMC
FDA Center for Drug Evaluation and Research Pegunigalsidase alfa multidiscipline review. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761161Orig1s000MultidisciplineR.pdf
Inker L.A., Schmid C.H., Tighiouart H., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–29. doi: 10.1056/NEJMoa1114248. PubMed DOI PMC
Delanaye P., Björk J., Vidal-Petiot E., et al. Diabetic status and the performances of creatinine- and cystatin C-based eGFR equations. Nephrol Dial Transplant. 2025;40:516–523. doi: 10.1093/ndt/gfae161. PubMed DOI
Russel W.A., Fu E.L., Bosi A., et al. Obesity, underweight, and accuracy of eGFR using cystatin C and creatinine in a northern European population. J Am Soc Nephrol. 2025;36:2177–2189. doi: 10.1681/ASN.0000000760. PubMed DOI PMC
